Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


EU Countries Examine Reasons For Wide Differences In Biosimilar Usage

Executive Summary

Speakers from several EU countries at last week's Medicines for Europe conference discussed the reasons behind the often wide inter-country disparities in biosimilar usage and the policies they are pursuing to try to remedy the situation.

You may also be interested in...

Global Regulators Caution Against Misinformation On Biosimilars

A coalition of the heads of medicines agencies from around world tells health care professionals that they have confidence in biosimilars, and address attempts made to spread misinformation on these products.

Biosimilar Interchangeability Policies Need Closer Alignment

Regulators should take more of a role in decisions on biosimilar switching and substitution, and international interchangeability practices should be brought into line, delegates at Medicines for Europe’s recent biosimilars conference heard.

Biosimilar Makers Take On ‘Huge’ Barriers To A Sustainable European Market

The biosimilars industry in Europe will face a struggle over the next few years as the longer-term sustainability of the market is threatened by a dearth of big biologic patent expiries and a growing number of new innovative drugs targeted at smaller patient populations. The Pink Sheet spoke to Adrian van den Hoven and Marc-Alexander Mahl of the generics and biosimilar medicines association, Medicines for Europe, about the sector’s key challenges and how they can be tackled.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts